

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/143440/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Scourfield, D. Oliver, Reed, Sophie G., Quastel, Max, Alderson, Jennifer, Bart, Valentina M. T., Teixeira Crespo, Alicia, Jones, Ruth, Pring, Ellie, Richter, Felix Clemens, Ahern, David J., Almuttaqi, Hannah, Alonzi, Dominic S., Alrubayyi, Aljawharah, Alsaleh, Ghada, Bart, Valentina M. T., Batchelor, Vicky, Bayliss, Rebecca, Berthold, Dorothee L., Bezbradica, Jelena S, Bharuchq, Tehmina, Borrmann, Helene, Borsa, Mariana, Borst, Rowie, Brun, Juliane, Burnell, Stephanie E. A., Capitani, Lorenzo, Cavounidis, Athena, Chapman, Lucy, Chauveau, Anne, Cifuentes, Liliana, Codd, Amy Susan, Compeer, Ewoud Bernardus, Coveney, Clarissa, Cross, Amy, Danielli, Sara, Davies, Luke C, Dendrou, Calliope A., Dimonte, Sandra, Peter Durairaj, Ruban Rex, Dustin, Lynn B., Dyer, Arthur, Fielding, Ceri, Fischer, Fabian, Gallimore, Awen, Galloway, Sarah, Gammage, Anís, Gea-Mallorquí, Ester, Godkin, Andrew, Hanna, Stephanie Jean, Heuberger, Cornelia, Hulin-Curtis, Sarah, Issa, Fadi, Jones, Emma, Jones, Ruth, Ladell, Kristin, Lauder, Sarah N., Liddiard, Kate, Ligoxygakis, Petros, Lu, Fangfang, MacLachlan, Bruce, Maleki-Toyserkani, Shayda, Mann, Elizabeth H., Marzeda, Anna M., James Matthews, Reginald, Mazet, Julie M., Milicic, Anita, Mitchell, Emma, Moon, Owen, Nguyen, Van Dien, O'Hanlon, Miriam, Eléonore Pavillet, Clara, Peppia, Dimitra, Pires, Ana, Pring, Eleanor, Quastel, Max, Reed, Sophie, Rehwinkel, Jan, Richmond, Niamh, Richter, Felix Clemens, Robinson, Alice J. B., Rodrigues, Patrícia R. S., Sabberwal, Pragati, Sami, Arvind, Peres, Raphael Sanches, Sattentau, Quentin, Schonfeldova, Barbora, Scourfield, David Oliver, Selvakumar, Tharini A., Shepherd, Freya R., Shorten, Cariad, Simon, Anna Katharina, Smith, Adrian L., Crespo, Alicia Teixeira, Tellier, Michael, Thornton, Emily, Uhl, Lion F. K., van Grinsven, Erinke, Wann, Angus K. T., Williams, Richard, Wilson, Joseph D., Zhou, Dingxi, Zhu, Zihan and Burnell, Stephanie E. A. 2021. The role and uses of antibodies in COVID-19 infections: a living review. *Oxford Open Immunology* 2 (1), iqab003. 10.1093/oxfimm/iqab003 file

Publishers page: <http://dx.doi.org/10.1093/oxfimm/iqab003>
<<http://dx.doi.org/10.1093/oxfimm/iqab003>>

Please note:

Changes made as a result of publishing processes such as copy-editing, proof correction and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You

information services
gwasanaethau gwybodaeth



are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.

The Role and Uses of Antibodies in COVID-19 Infections

Review

D. Oliver Scourfield^{1*}, Sophie G. Reed¹, Max Quastel², Jennifer Alderson³, Valentina M.T Bart¹, Alicia Teijeira Crespo⁴, Ruth Jones⁵, Ellie Pring¹, Felix Clemens Richter³, The Oxford-Cardiff COVID-19 Literature Consortium^{1,2,3,4,#} and Stephanie E.A Burnell^{1*}

*Equivalent Contributors

¹Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

²Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Headington, Oxford, OX3 7FZ, UK

³Kennedy Institute of Rheumatology, NDORMS, University of Oxford, OX3 FTY, UK

⁴Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN UK

⁵Dementia Research Institute, Haydn Ellis Building, Maindy Road, Cardiff University, Cardiff, CF24 4HQ

#Appendix 1

Address for correspondence: Stephanie Burnell and Oliver Scourfield, Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK. BurnellS@Cardiff.ac.uk and ScourfieldDO@Cardiff.ac.uk

Running Title: Antibodies in COVID-19

Keywords: Antibodies, COVID-19, SARS-CoV-2, Convalescent Plasma, Nanobodies, Vaccines, Long Term Immunity

Word count (main text): 2575

Abstract word count: 92

Number of Tables: 4

Number of Figures: 2

Number of Text boxes: 2

Abbreviations:

ACE2: Angiotensin-Converting Enzyme 2

APACHE-II: Acute Physiology and Chronic Health Evaluation II

COVID-19: Coronavirus disease 2019

CP: Convalescent Plasma

d.p.s.o: Days post symptom onset

FDA: Food and Drug Administration

IgM/IgA/IgG: Immunoglobulin M/A/G

mAb: Monoclonal Antibody

MERS: Middle East Respiratory Syndrome

nAb: Neutralising Antibody

NP: Nucleocapsid Protein

RBD: Receptor Binding Domain

RECOVERY: Randomised Evaluation of COVID-19 Therapy

S: Spike

SARS: Severe Acute Respiratory Syndrome

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

Abstract

COVID-19 has generated a rapidly evolving field of research, with the global scientific community striving for solutions to the current pandemic. Characterising humoral responses towards SARS-CoV-2, as well as closely related strains, will help determine whether antibodies are central to infection control, and aid the design of therapeutics and vaccine candidates. This review outlines the major aspects of SARS-CoV-2-specific antibody research to date, with a focus on the various prophylactic and therapeutic uses of antibodies to alleviate disease in addition to the potential of cross-reactive therapies and the implications of long-term immunity.

Introduction

Humoral immunity is a vital aspect of the immune system highly implicated in infection control. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a highly infectious virus that is responsible for the current worldwide COVID-19 pandemic. Understanding the immune response to this virus is paramount to limit disease burden in the population, and to discover new therapeutic options. One such response is that of antibodies; the immunoglobulins secreted by B-cells following antigen recognition. Antibodies have a multitude of effector functions and can coordinate the responses of other immune cells, including T-cells and macrophages, to eliminate pathogens. Studying the antibody response to SARS-CoV-2 will aid in vaccine design and the understanding long-term immunity prospects. Additionally, antibodies that bind and neutralise the SARS-CoV-2 virus have potential to be used as therapies for patients in the various forms of convalescent plasma (CP), monoclonal antibodies (mAbs) and nanobodies, all of which are discussed within this review.

Antibody responses to SARS-CoV-2 in different patient populations

Immunoglobulins IgM, IgA and IgG are key components of the antibody response towards SARS-CoV-2 and differ in titre and duration of response, as with other viral infections (**Figure 1**) (1). **Table 1** summarises the SARS-CoV-2 antibody literature to date. This includes seroconversion; how long it takes antibodies to be detected in the serum following infection, response kinetics; how long it takes antibodies to achieve their peak titre, and the prediction of response duration.




Figure 1: Changes in antibody concentration in response to viral infection. Following exposure to the virus and the initial incubation period of around 5 days, the infection takes hold. During the infection period patients may

develop symptoms as the first virus-specific antibodies are produced and the immune system is activated. IgM and IgA are produced initially, followed by IgG, which increases more slowly, but remains in the blood for a longer period, even after the infection has been cleared from the body. During the recovery and convalescent phases of infection the viral RNA reduces to undetectable levels before being removed from the system completely. IgA levels can persist, particularly at the mucous membranes (2-4), it is currently unclear how long the IgG titres last.

	IgM	IgA	IgG
% Seroconversion	>73 % (5-9)	>72% (5, 6, 10)	84-100% (5-12)
Seroconversion (d.p.s.o)	10-14 (8, 13-16)	13 (16)	12-14 (8, 13-16)
Peak titre (d.p.s.o)	15-30 (3-5, 7, 9, 14, 17-19)	16-30 (3, 5, 20-23)	16-50 (3-7, 9, 17, 19, 20, 22-24)
Median seronegative prediction	46.9 days (6)	51.0 days (6)	

Table 1: Summary of analysis of IgM, IgA and IgG responses to SARS-CoV-2 infection. Following infection by SARS-CoV-2, IgM, IgA and IgG are rapidly seroconverted within the first two weeks; IgM and IgA appear to reach their peak titre at similar days post symptom onset (d.p.s.o), whereas IgG often peaks at a later time point.

IgG levels were shown to peak earlier in asymptomatic and mild cases compared to severe cases (~20 vs ~35 days post symptom onset, d.p.s.o) and most asymptomatic patients, many of whom were children, had low or undetectable IgM levels, leading to speculation that high and persistent IgM may result in more severe symptoms (19, 21, 25-27). Interestingly, many publications have shown significant correlations of higher antibody titres in both older patients and those with more severe disease (7, 13, 17, 19, 28-30). Relative levels of IgA and IgG have been reported to be significantly higher in severe patients in addition to a significant correlation between IgA levels and APACHE-II score in critically ill patients (16, 23). A study investigating the specificity and functionality of antibody responses in children, found that SARS-CoV-2 positive children had low levels of IgM, IgA and IgG when compared to severe COVID-19 adults and demonstrated that children predominantly generated an anti-S IgG response compared to the broader antibody response generated by adults (31). It has been suggested that the reduced symptoms demonstrated by children could be due to the reduced expression of the viral receptor in children or that children generate a more robust innate immune response (32, 33).

In addition to age, biological sex is also a potential factor in COVID-19 disease severity. Several countries have reported higher hospital admissions and mortality rates in males, with a case fatality rate 1.7 times higher for men than for women (34). The production of IgG appears to be higher in females in the early stages of infection, possibly preventing the progression to advanced disease and decreasing the mortality rate (35, 36). Patients that succumb to SARS-CoV-2 infection were unable to generate a functional IgG response, coordinate Fc receptor binding and produce innate immune effector binding (37). Further to this, patients with severe COVID-19, particularly males, have been

shown to generate IgG1 antibodies with significantly reduced Fc fucosylation, in addition to increased IgG3 antibodies when compared to patients with mild symptoms and children, indicating that severe COVID-19 resulted from the production of proinflammatory IgG antibodies (38).

Coordinated responses between B cells, CD4⁺ and CD8⁺ T-cells are necessary to control and clear infection, without a functional B cell response, virus-specific memory T cells cannot provide complete protection (39). Neutralising antibody (nAb) responses and B cell memory decline over time and depend on CD4⁺ T-cell help, leaving the role of long-term protection to the memory T-cells (40, 41). This therefore indicates that the immune system as a whole must be analysed, in addition to the individual components, to understand why some people are asymptomatic while others succumb to the disease.

The use of antibodies as therapy for COVID-19

There are various strategies to treat SARS-CoV-2 infection with antibodies, as summarised in **Figure 2**. Plasma extracted from recovered COVID-19 patients is known as convalescent plasma (CP). CP contains antibodies of various diversity (polyclonal) and affinities to SARS-CoV-2 and was greatly employed during the early phases of the pandemic. More recently, monoclonal antibodies (mAbs) and nanobodies/sybodies have been developed. By isolating memory B cells from recovered patients and immunised animals or screening of antibody mRNA using phage display, highly selective candidates with high neutralisation capacity have been identified. Neutralising responses to SARS-CoV-2 target the receptor-binding domain (RBD) of the spike (S) glycoprotein, which is required to interact with the target receptor angiotensin-converting enzyme 2 (ACE2) on host cells (42-48). Steric hindrance of the RBD-ACE2 interaction by antibodies will block viral entry and prevent infection. It should be noted that other neutralising epitopes, distant from the RBD, exist but are less studied (43-50).




Figure 2: SARS-CoV-2-specific antibodies can be utilised in multiple ways to treat COVID-19. A) Sera from recovered COVID-19 patients can be given intravenously as convalescent plasma to ABO-matched infected patients in order to reduce infectious burden and alleviate active disease. (B) Monoclonal antibodies (typically IgG) can be identified following isolation of spike/RBD-specific memory B cells, which are sourced from recovered patients or mice immunised with target antigen. Potential candidates are screened for various parameters, including specificity to target antigen and neutralisation capacity. Selected lead candidates are further optimised before clinical evaluation as both a prophylactic and therapeutic. (C) The epitope binding domain of antibody heavy chains (VHH) also have therapeutic potential. These can be isolated following immunisation of camelids (nanobodies) or by using synthetic libraries (sybodies). The diversity of VHH mRNA is screened (e.g., using phage display) to identify those that have high affinity to the target antigen. Like monoclonal antibodies, these are evaluated for their specificity and neutralisation capacity before clinical evaluation. Figure created using BioRender.com

Convalescent plasma (CP)

CP has been used to successfully reduce mortality in a variety of viral epidemics, including influenza, SARS, and MERS (51, 52). During the current COVID-19 pandemic, several studies have investigated CP transfusions with high nAb titres as a treatment option (see **Figure 2A**). Plasma is harvested from donors with total anti-spike IgG titres of $>1:320$ using plasmapheresis, this can then be transfused into an ABO-compatible patient (53). **Table 2** summarises studies investigating the use of CP in COVID-19 patients.

Author and study type	Dose	# of Patients	Patient Severity	Administration	Patient Outcomes
Li <i>et al</i> (54) Open label randomised clinical trial	>1:640 S-RBD specific IgG	103	Control group: 29 life-threatening, 22 severe CP group: 29 life-threatening, 23 severe	4-13 ml/kg of recipient body weight	Mortality: 15.7% CP group vs 24% control p = 0.30 Clinical improvement: Severe patients 91.3% CP group vs 68.2% control p = 0.03 Critically ill patients 20.7% CP group vs 24.1% control p = 0.83
Duan <i>et al</i> (55) Case series	>1:640 nAb	10	10 severe	1 dose of 200 ml	All recovered No severe adverse effects observed
Shen <i>et al</i> (56) Case series	>1:80 nAb	5	5 critically ill	2 transfusions of 200 ml	Of the 5 patients, 3 discharged and 2 were in stable condition
Liu <i>et al</i> (53) Matched control	≥1:320 S-specific IgG	39	CP group: 39 severe to life-threatening Matched controls: 152 severe to life-threatening	2 transfusions of 250ml	12.8% mortality for CP group 24.4% mortality for matched controls (p = 0.039) CP improved survival in non-intubated patients (p = 0.015) but not for intubated patients (p = 0.752)
Donato <i>et al</i> (57) Case series	>1:500 nAb	47	32 non-mechanically ventilated, 22% immunocompromised and 19% had active cancer 15 mechanically ventilated	400ml - 500ml	Non-mechanically ventilated: 15.6% intubation rate compared to institutional data (not reported; p = 0.038) 87.5% survival rate compared to 66% from institutional data (p = 0.012) Mechanically ventilated: 46.7% 30-day mortality rate compared to institutional data 68.5% (p = 0.093)
Agarwal <i>et al</i> Open label randomised control trial (58)	>1:20 nAb	464	Moderate illness	2 transfusions of 200ml	Progression to severe disease or mortality: 19% CP group vs 18% control

<i>Simonovich et al (59)</i> Double-blinded randomised control	>1:800 S-specific IgG	333	Patients with severe COVID-19 pneumonia	5-10 ml/kg of recipient body weight	Mortality: 10.96% CP group vs 11.43% control
---	-----------------------	-----	---	-------------------------------------	--

Table 2: Information to show the CP treatment regimen and outcome of several COVID-19 studies

An early meta-analysis of CP treatment for COVID-19 found evidence of reduced mortality as well as increased viral clearance, and clinical improvements (60). Additionally, a more recent meta-analysis of larger, better quality studies confirmed these findings (61). However, both the PLACID and PlasmAr randomised trials found no differences in disease progression or mortality in COVID-19 patients receiving CP or best standard of care/placebo (58, 59). Larger, blinded, randomised control trials are still ongoing to confirm the efficacy of CP treatment, the RECOVERY trial in Oxford is one such phase 3 trial of convalescent plasma (NCT04381936).

In SARS patients, early CP treatment within 14 days of infection significantly improved outcomes (62). This has also been suggested for COVID-19, but more studies are required to fully evaluate this (55). Recovered patients with high nAb titres have relatively stable levels but these do decrease over time. Gontu *et al.* observed that the optimal time window for recovered patients to donate plasma is within 60 d.p.s.o (9).

Finally, CP treatment could be particularly beneficial for individuals who are immunocompromised (63, 64). The nAbs in CP are likely targeted to a range of SARS-CoV-2 S protein epitopes, which is advantageous compared to single or even 'cocktail' mAb treatment where there is greater likelihood of escape mutations (65).

Monoclonal Antibodies (mAbs)

Many studies have tested the neutralising capacity of mAbs against SARS-CoV-2 *in vitro* (**Figure 2B**) and assessed their functionality *in vivo*. Neutralising mAbs have shown a reduction in viral load and protection from challenge in animal models (42, 44-50, 66, 67). This ability to inhibit infection highlights mAbs as potential therapeutic candidates for COVID-19.

Multiple candidates are in advanced clinical trials (**Table 3**). Recently, two mAb therapies (bamlanivimab, formerly LY-CoV555, and REGN-COV2) have received emergency use authorisation by the Food and Drug Administration (FDA) to prevent mild-to-moderately infected patients from

progressing to severe disease. Whilst bamlanivimab is a single mAb isolated from the B cells of a convalescent patient (68), REGN-COV2 is a cocktail of two mAbs (casirivimab and imdevimab) identified using both recovered patients and humanised mice (69). Casirivimab and imdevimab recognise non-overlapping epitopes on the RBD which may overcome resistance posed by “viral escape” mutations, such as D614G, a missense mutation in the spike protein that results in a more transmissible form of SARS-CoV-2 (70). This approach of “antibody cocktails” is also being explored by AstraZeneca, with their candidate AZD7442, comprising two mAbs, recently entering phase 3 trials (42).

Company	mAb name	Comments	Stage of Development	Study Group
Eli Lilly and Company (Developed with AbCellera)	Bamlanivimab* (LY-CoV555/ LY3819253)	Human IgG1 isolated from convalesced patient using high-throughput microfluidic screening (68)	Phase 3 - NCT04497987 “BLAZE-2”	Nursing Home residents and staff
			Phase 3 - NCT04501978 “ACTIV-3”	Inpatients
			Phase 2/3 - NCT04518410 “ACTIV-2”	Outpatients
			Phase 1 - NCT04537910	Healthy Participants
	LY-CoV555 (LY3819253) + LY-CoV016 (LY3832479)	Combination therapy (71)	Phase 2 - NCT04427501 “BLAZE-1”	Mild to Moderate Illness
Regeneron Pharmaceuticals	REGN-COV2* (Casirivimab + Imdevimab)	Identified from humanised mice and convalescent samples. This dual-antibody cocktail target non-overlapping epitopes (69)	Phase 3 - NCT04452318	Healthy adults who are household contacts with a positive case
			Phase 2/3 - NCT04381936 “RECOVERY”	COVID-19 Patients
			Phase 1/2 - NCT04425629	Ambulatory COVID-19 patients
			Phase 1/2 - NCT04426695	Hospitalised patients
			Phase 1 NCT04519437	Volunteers – Healthy, Chronic stable illness
Vir Biotechnology/ GlaxoSmithKline	Sotrovimab (VIR-7831/GSK4182136)	Fully human based on S309 IgG which was isolated from the memory B-cells of an individual recovered from SARS-CoV (cross-reactive) (47)	Phase 2/3 - NCT04545060 “COMET-ICE”	Patients who are at high risk of hospitalisation
AstraZeneca	AZD7442 (Tixagevimab + Cilgavimab)	Antibodies with non-overlapping epitopes identified from a convalescent patient (42). The antibodies have been optimised to extend half-life so they should be prevalent for 6-12	Phase 3 - NCT04625972 “STORM CHASER”	Adults with potential recent (within 8 days) exposure to a confirmed positive case
			Phase 3 – NCT04625725 “PROVENT”	Adults who have no history of SARS-CoV-2 but have been exposed

		months – “Long-Acting Antibody Combination”		
Celltrion	Regdanvimab (CT-P59)	Targets the RBD of the spike protein	Phase 2/3 - NCT04602000	Diagnosed outpatients with mild conditions

Table 3: Current leading monoclonal antibody therapies against SARS-CoV-2 Spike/RBD in clinical trials. Included are the most advanced candidates, determined as those which have entered phase 2/3 clinical stage. *denotes those which have received emergency use authorisation by the FDA. Table created with aid from Yang *et al* (72).

Cross-Reactive nAb Therapies

Multiple SARS-CoV and MERS-CoV mAbs were identified following the Severe Acute Respiratory (SARS) and Middle East Respiratory Syndrome (MERS) epidemics in 2003 and 2012, respectively (73). However, therapeutic developments were limited due to the short duration of these outbreaks. Both SARS-CoV and SARS-CoV-2 utilise ACE2 as their cell-entry receptor and the S-glycoprotein of SARS-CoV-2 is over 70% identical to that of SARS-CoV (74-79). Conversely, MERS-CoV binds to the CD26 receptor and is less homologous to SARS-CoV-2 (79, 80). Antibody cross-reactivity could potentially allow repurposing of these SARS-CoV mAbs to combat COVID-19.

RBD-directed mAbs, which interfere with ACE2 binding, thereby neutralising SARS-CoV (e.g. 80R, CR3014), were unable to bind to SARS-CoV-2-RBD (81, 82). Conversely, multiple SARS-CoV targeted mAbs, which do not compete with ACE2, have shown potent cross-neutralising capacity including 47D11 and CR3022 (82-84). The ability of CR3022 to neutralise SARS-CoV-2 has been disputed by Yuan *et al.*, however, who used a pseudovirus neutralisation assay to assess this rather than one with live virus as with Huo *et al.* (84, 85). A further explanation for the differences seen is that antibodies which show cross-reactivity recognise epitopes that are highly conserved between the strains. For example, the epitope of CR3022 is 86% conserved between SARS-CoV and SARS-CoV-2, and the more recently identified S309 (see **Table 3**) binds an epitope which is 77% conserved (47, 85). Additional work has shown that further increasing the conservation of CR3022’s epitope vastly increases the antibody’s affinity to SARS-CoV-2 RBD, suggesting that antibody cross-reactivity is highly dependent on epitope recognition (86).

Nanobodies

Efforts have also been directed towards the development of nanobodies to treat COVID-19 (**Figure 2C**). Sequences of these single-domain antibodies (VHH) capable of blocking the RBD/ACE2 interaction and neutralise SARS-CoV-2 have been identified using synthetic libraries (synthetic nanobodies,

sybodies) and camelids (nanobodies), which produce heavy-chain-only antibodies (13, 87-95). Nanobodies have multiple benefits over conventional antibodies such as their biophysical and biochemical characteristics, and ease of manufacture and varied administrative potential (e.g. via inhalation) (91, 96).

Recent literature has shown a variety of ways in which antibodies can be used as treatment for COVID-19. While CP may work as a polyclonal approach, monoclonal antibodies and nanobodies recognising the RBD epitope of the virus are more promising since they are potent, high titre, relatively safe and can be readily manufactured in bulk. Because of this, multiple candidates are reaching clinical trials within a short timescale. Candidates recognising epitopes that are highly conserved between coronaviruses have scope as potential pan-coronavirus therapies and may protect individuals from future epidemic/pandemic strains.

Antibody Responses to SARS-CoV-2 vaccines and long-term immunity

Prophylactic vaccines are in development to protect against COVID-19, with the aim of inducing nAb and T cell responses to combat infection. *In vivo* antiviral efficacy has been demonstrated in animal models, including preventing infection when challenged, and is being tested in clinical trials (97-117).

The majority of vaccines include the whole SARS-CoV-2 spike protein, and may also include the nucleocapsid protein (NP), while others only employ the RBD (97-109, 112-117). The NP antigen does not generate antibodies that are neutralising against SARS-CoV-2, whereas RBD and spike protein antigens elicit nAb responses (102). The RBD and S1 domain of the spike protein unsurprisingly produce the greatest nAb responses, as these domains are responsible for ACE2 binding and gaining entry to host cells (118, 119). Smith *et al.* and Yarmarkovich *et al.* took a computational approach to predict epitopes that produce humoral and cell-mediated responses, which may be broadly protective across various coronaviruses (120, 121). Unfortunately, some non-neutralising antibodies may have the potential to bridge viral entry into host immune cells via Fc receptors, known as Antibody Dependent Enhancement (ADE). This leads to increased infectivity, higher viral loads, more severe disease and has been observed in previous SARS/MERS vaccines (122). Thus far, no study has yet shown evidence of vaccine-induced ADE for SARS-CoV-2.

The duration of long-term immunity to SARS-CoV-2 following infection or vaccination, as well as the level of nAb required for immunity is currently unknown. Using a mathematical model of antibody kinetics determined by follow-up of coronavirus convalescent patients, one study has predicted that antibody responses will decline according to a bi-phasic pattern – a rapid decline initially, followed by

a slower rate of decay (123). This study indicated that, due to the substantial initial reduction of antibodies, up to 50% of patients could test sero-negative after just one year (123). Although these results cannot be verified until those patients are followed for several years following infection, other studies have estimated the time of sero-reversion of SARS-CoV-2 antibodies based on the time taken for patients to become sero-negative; 46.9 days for IgM and 51 days for IgA, as of yet, there is no consensus on IgG (**Table 1**) (6). Neutralising antibody titres initially increase and remain stable for 3-4 months (5, 124-127). Individuals with high peak nAb titres were observed to maintain these, but levels decreased to those of less severe groups at >90 d.p.s.o. (5, 127).

The duration of the immune response resulting from seasonal coronavirus infection varies, but the results obtained from these can help predict the duration of antibody responses until longer-term studies with large cohorts of patients can be carried out for SARS-CoV-2. Previous work carried out on SARS-CoV has indicated convalescent patients remained IgG positive for 2-4 years and antibody responses declined after 2-3 years, with severely affected individuals more likely to maintain detectable responses (128-134). However, antibody responses for 6 out of 9 volunteers inoculated with seasonal coronavirus strain 229E were no longer sufficient to prevent re-infection one year later (135). Furthermore, a 35-year-long study found that most seasonal coronavirus reinfections occurred every 3 years, depending on re-exposure and lingering immunity (136). Adapted seasonal coronavirus modelling estimates that SARS-CoV-2 immunity may last approximately 45 weeks, but an antibody response may not confer complete protection from re-infection (133, 137).

Reinfection has been reported in a number of cases, summarised in **Table 4**. The majority of the re-infected individuals had an initial mild or asymptomatic infection, and these may not elicit a sufficiently robust antibody response to be sustained and protective since patients whose nAb responses were measured had low to undetectable responses (138-145). These reinfection cases highlight that since most cases of COVID-19 will be mild, reinfection is possible especially following a reduction in nAbs and the possibility of spike protein mutations that reduce nAb binding affinity (65). Two patients were re-infected with a D614G variant, and one patient was reinfected with a N440K variant, which is a known nAb escape mutation (65, 140, 141, 143). A recent study has demonstrated that although antibody titres decrease substantially over time, neutralisation activity is retained for up to 6 months (146). Longer studies involving more individuals are required to evaluate when people might become vulnerable to reinfection. This work supports a vaccine-based approach to controlling SARS-CoV-2 transmission but if serology of vaccinated individuals follows a similar pattern to those who have recovered, then regular boosters may be required.

Location	Patient: Age (years) and Sex (M/F)	Severity of first infection	Severity of second infection	Days between first and second infection	Reference
Hong Kong	34 (M)	Mild	Asymptomatic	142	(138)
United States	25 (M)	Mild	Severe	48	(139)
	42 (M)	Mild	Moderate	51	(140)
	60-69*	Severe	Mild	118	(141)
Ecuador	46 (M)	Mild	Moderate	47	(142)
India	25 (M)	Asymptomatic	Asymptomatic ⁺	100	(143)
	28 (F)	Asymptomatic	Asymptomatic ⁺	101	
	27 (M)	Mild	Moderate	66	(144)
	31 (M)	Asymptomatic	Mild	65	
	27 (M)	Asymptomatic	Mild	19	
	24 (F)	Mild	Moderate	55	

Table 4: A summary of SARS-CoV-2 reinfection cases confirmed by whole genome sequencing. *Patient details only gave age range of 60-69. ⁺Asymptomatic but had a higher viral load upon reinfection.

Conclusion

Antibodies are an important aspect of the immune response to COVID-19. While there remains a lot to learn, it is encouraging to see that in a matter of months, many promising antibody-based prophylactics and therapies are making their way into the clinic. Considering the number of reported cases of SARS-CoV-2 reinfection, the uncertainty surrounding long-term immunity will hopefully be more conclusively addressed in the months to come. To date the current estimate of antibody longevity is 46.9 days for IgA and 51 days for IgM, with no consensus on IgG. Reinfections have occurred between 19 and 142 days, with the majority greater than 50 days, after recovery from the first infection, resulting in both mild and severe illness. These numbers could change greatly in the coming months and may not be representative of the population. It is important to stress that antibodies aren't the sole immune defence against COVID-19, and many vaccines aim to elicit general adaptive immune responses. Evaluating the collective immune response to SARS-CoV-2 will advance our understanding of the mechanism of disease and its control.

Acknowledgements

We would like to thank Professor Awen Gallimore, Professor Paul Morgan, Dr Wioleta Zelek, Dr Jakub Kopycinski, Dr Gemma Hancock and Professor Quentin Sattentau for their help, suggestions and expertise when writing this manuscript. We would also like to thank the Oxford-Cardiff COVID-19 Literature Consortium for initiating these COVID-19 discussions and providing the opportunity to write this review.

Conflicts of Interest

The authors declare no conflicts of interest

Data Availability Statement

There are no new data associated with this article

Author Contributions

Conceptualisation: SEAB, DOS

Supervision: SEAB and FCR

Writing – original draft: SEAB, DOS, SGR, VB, ATC, RJ, EP and The Oxford-Cardiff COVID-19 Literature Consortium

Writing – review & editing: SEAB, DOS, SGR, MQ and JA

Appendix 1

David J Ahern¹, Hannah Almuttaqi¹, Dominic S Alonzi⁴, Aljawharah Alrubayyi⁷, Ghada Alsaleh¹, Valentina M.T Bart¹⁶, Vicky Batchelor¹, Rebecca Bayliss¹⁵, Dorothee L Berthold¹, Jelena S Bezbradica¹, Tehmina Bharuchq⁴, Helene Borrmann⁷, Mariana Borsa¹, Rowie Borst¹, Juliane Brun⁴, Stephanie E.A Burnell¹⁶, Lorenzo Capitani¹⁶, Athena Cavounidis¹⁰, Lucy Chapman¹⁶, Anne Chauveau¹, Liliana Cifuentes¹, Amy Susan Codd¹⁶, Ewoud Bernardus Compeer¹, Clarissa Coveney¹, Amy Cross⁹, Sara Danielli¹, Luke C Davies¹⁶, Calliope A Dendrou⁵, Sandra Dimonte¹⁶, Ruban Rex Peter Durairaj¹⁶, Lynn B Dustin¹, Arthur Dyer¹³, Ceri Fielding¹⁶, Fabian Fischer¹, Awen Gallimore¹⁶, Sarah Galloway¹⁶, Anís Gammage¹, Ester Gea-Mallorquí¹, Andrew Godkin¹⁶, Stephanie Jean Hanna¹⁶, Cornelia Heuberger¹, Sarah Hulin-Curtis¹⁶, Fadi Issa⁹, Emma Jones¹⁶, Ruth Jones¹⁸, Kristin Ladell¹⁶, Sarah N Lauder¹⁶, Kate Liddiard¹⁵, Petros Ligoxygakis¹², Fangfang Lu³, Bruce MacLachlan¹⁶, Shayda Maleki-Toyserkani¹⁶, Elizabeth H Mann¹, Anna M Marzeda¹, Reginald James Matthews¹⁹, Julie M Mazet¹, Anita Milicic¹⁷, Emma Mitchell¹⁶, Owen Moon¹⁶, Van Dien Nguyen¹⁶, Miriam O'Hanlon¹, Clara Eléonore Pavillet⁶, Dimitra Peppas⁷, Ana Pires¹⁶, Eleanor Pring¹⁶, Max Quastel⁸, Sophie Reed¹⁶, Jan Rehwinkel², Niamh Richmond¹, Felix Clemens Richter¹, Alice JB Robinson¹, Patrícia R S Rodrigues¹⁶, Pragati Sabberwal¹⁶, Arvind Sami¹¹, Raphael Sanches Peres¹, Quentin Sattentau³, Barbora Schonfeldova¹, David Oliver Scourfield¹⁶, Tharini A Selvakumar⁸, Freya R Shepherd¹⁶, Cariad Shorten⁶, Anna Katharina Simon¹, Adrian L Smith¹⁴, Alicia Teijeira Crespo¹⁵, Michael Tellier³, Emily Thornton², Lion F K Uhl¹, Erinke van Grinsven¹, Angus K T Wann¹, Richard Williams¹, Joseph D Wilson⁶, Dingxi Zhou¹, Zihan Zhu³

Affiliations of Consortium members

¹ Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

² Medical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

³ Sir William Dunn School of Pathology, Medical Science Division, University of Oxford, Oxford, United Kingdom

⁴ Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford, United Kingdom

⁵ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

⁶ Medical Sciences Division, University of Oxford, Oxford, United Kingdom

⁷ Nuffield Department of Clinical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

⁸ Nuffield Department of Medicine, University of Oxford, Oxford, UK

⁹ Nuffield Department of Surgical Sciences, University of Oxford, Oxford

¹⁰ Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

¹¹ Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

¹² Department of Biochemistry, University of Oxford, Oxford, United Kingdom

¹³ Department of Oncology, University of Oxford, Oxford, United Kingdom

¹⁴ Department of Zoology, University of Oxford, United Kingdom

¹⁵ Division of Cancer and Genetics, School of Medicine, Cardiff University, United Kingdom

¹⁶ Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom

¹⁷ The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

¹⁸ Dementia Research Institute, Haydn Ellis Building, Cardiff University, Cardiff, United Kingdom

¹⁹ Centre for Medical Education, School of Medicine, Cardiff University, Cardiff, United Kingdom

Living Review Text Boxes

What is the consensus on antibodies in SARS-CoV-2 infection?

When infected with COVID-19, patients produce antibodies to fight off the infection. These antibodies are known as immunoglobulins; IgM, IgA and IgG, and are key players in the response to COVID-19. Each have a unique role and therefore take different lengths of time to be detected in the blood, to reach the maximum quantity and diminish from the system. As this is still a new disease, further work is needed to determine how long these antibody responses last in the body. Most COVID-19 patients that do not display any symptoms have low levels of IgM, whilst levels of IgA and IgG antibodies are higher in more severe, symptomatic patients. However, more in-depth study is needed to see if these antibody responses are important in controlling infection and how they co-ordinate with other immune responses to COVID-19.

Patients with strong immune responses to COVID-19 have high levels of neutralising antibodies, which successfully control the infection. Once recovered, plasma can be taken from these patients and be administered to those who are currently severely infected. This is known as convalescent plasma treatment. Other treatment options, which include monoclonal antibodies and nanobodies, are more focused therapies, having developed from the most potent antibodies. Approval of two potent mAb therapies signifies the importance of antibodies in overcoming infection. However these are most effective at preventing severe disease, so research to identify treatments to benefit those severely infected is still needed. However, these are most effective at preventing progression to severe disease, so research to identify treatments to benefit those severely infected is still needed. Work is also being carried out to investigate previous coronavirus infections to see what we can learn from them. It is possible that antibodies made against these other strains may help protect people during this pandemic.

It is currently unknown whether people who have recovered from COVID-19 are protected against a future SARS-CoV-2 infection as reinfection has been reported in several people worldwide. This has implications for vaccine design as regular boosters may be required if the immune response declines. Key components to creating a long-lasting immunity to the virus will become clearer once further research has been conducted.

Why do antibodies in SARS-CoV-2 infection matter?

COVID-19 has rapidly changed the World, from countless deaths and long-term health problems in survivors, to creating a social and economic burden. Research on COVID-19 is being produced quickly, so it is crucial that we view this critically to distinguish robust data. From this baseline, we are then able to produce successful therapies as soon as possible to help fight this pandemic.

Looking at previous coronavirus strains is necessary to gain useful insights into this new and novel virus. There are similarities between SARS-CoV-2 and former strains we have faced, which give us invaluable knowledge in treating patients and limiting global disease burden. What we learn from COVID-19 may also be applied to future epidemic or pandemic strains.

Using antibodies taken from patients that have recovered from COVID-19 infection and giving them to those that are struggling to fight off the infection has the potential to save lives and bridge the gap while doctors and scientists are learning more about how to fight the virus and produce other treatments and vaccines.

References

1. Jacofsky D, Jacofsky EM, Jacofsky M. Understanding Antibody Testing for COVID-19. *J Arthroplasty*. 2020;35(7S):S74-S81.
2. Hsu DC. Janeway's Immunobiology. *Shock*. 2008;29(6):770.
3. Yao X-Y, Liu W, Li Z-Y, Xiong H-L, Su Y-Y, Li T, et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. *medRxiv*. 2020:2020.07.18.20156810.
4. Xiao AT, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: The first report. *Journal of Infection*. 2020;81(1):147-78.
5. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nature Microbiology*. 2020;5(12):1598-607.
6. Iyer AS, Jones FK, Nodoushania A, Kelly M, Becker M, Slater D, et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. *medRxiv*. 2020:2020.07.18.20155374.
7. Hu Q, Cui X, Liu X, Peng B, Jiang J, Wang X, et al. The production of antibodies for SARS-CoV-2 and its clinical implication. *medRxiv*. 2020:2020.04.20.20065953.
8. Lou B, Li T-D, Zheng S-F, Su Y-Y, Li Z-Y, Liu W, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. *European Respiratory Journal*. 2020;56(2):2000763.
9. Gontu A, Srinivasan S, Salazar E, Nair MS, Nissly RH, Greenawalt D, et al. Limited window for donation of convalescent plasma with high live-virus neutralizing antibodies for COVID-19 immunotherapy. *bioRxiv*. 2020:2020.08.21.261909.
10. Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al. Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. *J Infect Dis*. 2020;222(8):1265-9.
11. Phipps WS, SoRelle JA, Li Q-Z, Mahimainathan L, Araj E, Markantonis J, et al. SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity. *American Journal of Clinical Pathology*. 2020.
12. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann AJ, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Science immunology*. 2020;5(48):eabc8413.
13. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clinical Infectious Diseases*. 2020.
14. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature medicine*. 2020;26(6):845-8.
15. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020:ciaa979.
16. Yu H-q, Sun B-q, Fang Z-f, Zhao J-c, Liu X-y, Li Y-m, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. *European Respiratory Journal*. 2020:2001526.
17. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. *medRxiv*. 2020:2020.03.24.20042382.
18. Nakano Y, Kurano M, Morita Y, Shimura T, Yokoyama R, Qian C, et al. Time course of the sensitivity and specificity of serum anti-SARS-CoV-2 IgM and IgG antibodies for the diagnosis of symptomatic COVID-19 in Japan. 2020.
19. Li K, Huang B, Wu M, Zhong A, Li L, Cai Y, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. *Nature communications*. 2020;11(1):6044.

20. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Science immunology*. 2020;5(52):eabe5511.
21. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. *The Journal of allergy and clinical immunology*. 2020.
22. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Science Translational Medicine*. 2020:eabd2223.
23. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. *Cellular & Molecular Immunology*. 2020;17(7):773-5.
24. Gozalbo-Rovira R, Gimenez E, Latorre V, Francés-Gómez C, Albert E, Buesa J, et al. SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. *Journal of Clinical Virology*. 2020;131:104611.
25. Zhang Z, Xiao T, Wang Y, Yuan J, Ye H, Wei L, et al. Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers. *medRxiv*. 2020:2020.04.28.20083139.
26. Hansen CB, Jarlhelt I, Pérez-Alós L, Hummelshøj Landsy L, Loftager M, Rosbjerg A, et al. SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals. *The Journal of Immunology*. 2020:ji2000898.
27. Lei Q, Li Y, Hou H-y, Wang F, Ouyang Z-q, Zhang Y, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. *Allergy.n/a(n/a)*.
28. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, et al. Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020:ciaa721.
29. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv*. 2020:2020.03.30.20047365.
30. Hasan Ali O, Bomze D, Risch L, Brugger SD, Paprotny M, Weber M, et al. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
31. Weisberg SP, Connors TJ, Zhu Y, Baldwin MR, Lin W-H, Wontakal S, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nature immunology*. 2020.
32. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. *JAMA*. 2020;323(23):2427-9.
33. Pierce CA, Preston-Hurlburt P, Dai Y, Aschner CB, Cheshenko N, Galen B, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Science Translational Medicine*. 2020;12(564):eabd5487.
34. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nature Reviews Immunology*. 2020;20(7):442-7.
35. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex. *Journal of Medical Virology*. 2020;92(10):2050-4.
36. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. *The American journal of pathology*. 2020:S0002-9440(20)30489-2.
37. Zohar T, Loos C, Fischinger S, Atyeo C, Wang C, Slein MD, et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. *Cell*. 2020;183(6):1508-19.e12.

38. Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. *Nature immunology*. 2020.
39. Xu R-H, Fang M, Klein-Szanto A, Sigal LJ. Memory CD8+ T cells are gatekeepers of the lymph node draining the site of viral infection. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(26):10992-7.
40. Rydzynski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*. 2020;183(4):996-1012.e19.
41. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. *Immunol Res*. 2014;59(1-3):118-28.
42. Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. *Nature medicine*. 2020;26(9):1422-7.
43. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*. 2020.
44. Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science (New York, NY)*. 2020;368(6496):1274-8.
45. Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. *Cell*. 2020.
46. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. *Nature*. 2020.
47. Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*. 2020;583(7815):290-5.
48. Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. *Science (New York, NY)*. 2020.
49. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science (New York, NY)*. 2020:eabc6952.
50. Poh CM, Carissimo G, Wang B, Amrun SN, Lee CY-P, Chee RS-L, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. *Nature communications*. 2020;11(1):2806.
51. Al-Tawfiq JA, Arabi Y. Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19. *Human Vaccines & Immunotherapeutics*. 2020:1-7.
52. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis*. 2015;211(1):80-90.
53. Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. *Nature medicine*. 2020.
54. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA*. 2020.
55. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proceedings of the National Academy of Sciences*. 2020;117(17):9490-6.
56. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA*. 2020;323(16):1582-9.
57. Donato M, Park S, Baker M, Korngold R, Morawski A, Geng X, et al. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study. *medRxiv*; 2020.

58. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ*. 2020;371:m3939.
59. Simonovich VA, Burgos Pratz LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *New England Journal of Medicine*. 2020.
60. Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. *Journal of Medical Virology*.n/a(n/a).
61. Joyner MJ, Klassen SA, Senefeld J, Johnson PW, Carter RE, Wiggins CC, et al. Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. *medRxiv*. 2020:2020.07.29.20162917.
62. Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *European Journal of Clinical Microbiology and Infectious Diseases*. 2005;24(1):44-6.
63. Clark E, Guilpain P, Filip IL, Pansu N, Le Bihan C, Cartron G, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. *British Journal of Haematology*. 2020;190(3):e154-e6.
64. Wright Z, Bersabe A, Eden R, Cap A. Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2020:S2152-650(20)30310-4.
65. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *Elife*. 2020;9:e61312.
66. Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. *Science (New York, NY)*. 2020;370(6520):1110-5.
67. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science (New York, NY)*. 2020;369(6506):956-63.
68. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. *bioRxiv*. 2020:2020.09.30.318972.
69. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science (New York, NY)*. 2020;369(6506):1010-4.
70. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science (New York, NY)*. 2020;369(6506):1014-8.
71. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. *New England Journal of Medicine*. 2020.
72. Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. *Antibody Therapeutics*. 2020;3(3):205-12.
73. Shanmugaraj B, Siri wattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). *Asian Pacific journal of allergy and immunology*. 2020;38(1):10-8.
74. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*. 2003;426(6965):450-4.
75. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181(2):271-80.e8.

76. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3.
77. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Velesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 2020;181(2):281-92.e6.
78. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nature Microbiology*. 2020;5(4):562-9.
79. Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson J-P, et al. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses. *medRxiv : the preprint server for health sciences*. 2020:2020.06.22.20137695.
80. Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. *Cell Res*. 2013;23(8):986-93.
81. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science (New York, NY)*. 2020;367(6483):1260-3.
82. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerg Microbes Infect*. 2020;9(1):382-5.
83. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, et al. Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection. *Nature communications*. 2020;11(1):2511.
84. Huo J, Zhao Y, Ren J, Zhou D, Duyvesteyn HME, Ginn HM, et al. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. *Cell Host Microbe*. 2020:S1931-3128(20)30351-6.
85. Yuan M, Wu NC, Zhu X, Lee C-CD, So RTY, Lv H, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science (New York, NY)*. 2020;368(6491):630-3.
86. Wu NC, Yuan M, Bangaru S, Huang D, Zhu X, Lee C-CD, et al. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. *PLOS Pathogens*. 2020;16(12):e1009089.
87. Custódio TF, Das H, Sheward DJ, Hanke L, Pazicky S, Pieprzyk J, et al. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. *Nature communications*. 2020;11(1):5588.
88. Schoof M, Faust B, Saunders RA, Sangwan S, Rezelj V, Hoppe N, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. *Science (New York, NY)*. 2020:eabe3255.
89. Walter JD, Hutter CAJ, Zimmermann I, Wyss M, Egloff P, Sorgenfrei M, et al. Sybodies targeting the SARS-CoV-2 receptor-binding domain. *bioRxiv*. 2020:2020.04.16.045419.
90. Wrapp D, De Vlioger D, Corbett KS, Torres GM, Wang N, Van Breedam W, et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. *Cell*. 2020;181(6):1436-41.
91. Gai J, Ma L, Li G, Zhu M, Qiao P, Li X, et al. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. *bioRxiv*. 2020:2020.08.09.242867.
92. Hanke L, Vidakovics Perez L, Sheward DJ, Das H, Schulte T, Moliner-Morro A, et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. *Nature communications*. 2020;11(1):4420.
93. Huo J, Le Bas A, Ruza RR, Duyvesteyn HME, Mikolajek H, Malinauskas T, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. *Nature Structural & Molecular Biology*. 2020;27(9):846-54.
94. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2. *bioRxiv*. 2020:2020.03.13.990226.
95. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. *Nature*. 1993;363(6428):446-8.

96. Kolkman JA, Law DA. Nanobodies – from llamas to therapeutic proteins. *Drug Discovery Today: Technologies*. 2010;7(2):e139-e46.
97. McKay PF, Hu K, Blakney AK, Samnuan K, Brown JC, Penn R, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. *Nature communications*. 2020;11(1):3523.
98. Erasmus JH, Khandhar AP, O'Connor MA, Walls AC, Hemann EA, Murapa P, et al. An *Alphavirus*-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. *Science Translational Medicine*. 2020;12(555):eabc9396.
99. Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. *Nature communications*. 2020;11(1):2601.
100. Rice A, Verma M, Shin A, Zakin L, Sieling P, Tanaka S, et al. A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses. *bioRxiv*. 2020:2020.07.29.227595.
101. Routhu NK, Gangadhara S, Cheedarla N, Shiferaw A, Rahman SA, Sahoo A, et al. Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response. *bioRxiv*. 2020:2020.06.27.175166.
102. Chiuppesi F, Salazar MdA, Contreras H, Nguyen VH, Martinez J, Park Y, et al. Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. *Nature communications*. 2020;11(1):6121-.
103. Mandolesi M, Sheward DJ, Hanke L, Ma J, Pushparaj P, Vidakovics LP, et al. SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses. *bioRxiv*. 2020:2020.07.31.228486.
104. Zang J, Gu C, Zhou B, Zhang C, Yang Y, Xu S, et al. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. *Cell Discovery*. 2020;6(1):61.
105. Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. *Cell*. 2020;182(3):722-33.e11.
106. Quinlan BD, Mou H, Zhang L, Guo Y, He W, Ojha A, et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. *bioRxiv*. 2020:2020.04.10.036418.
107. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science (New York, NY)*. 2020;369(6505):806-11.
108. van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. *Nature*. 2020.
109. Tian J-H, Patel N, Haupt R, Zhou H, Weston S, Hammond H, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice. *bioRxiv*. 2020:2020.06.29.178509.
110. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. *Cell*. 2020;182(3):713-21.e9.
111. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. *Science (New York, NY)*. 2020;369(6499):77-81.
112. Jackson LA, Anderson EJ, Roupheal NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *The New England journal of medicine*. 2020.
113. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature*. 2020.
114. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. Concurrent human antibody and T_H1 type T-cell responses elicited by a COVID-19 RNA vaccine. *medRxiv*. 2020:2020.07.17.20140533.

115. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*. 2020;396(10249):467-78.
116. Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet*. 2020;396(10249):479-88.
117. Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *The Lancet*. 2020;395(10240):1845-54.
118. Ravichandran S, Coyle EM, Klenow L, Tang J, Grubbs G, Liu S, et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. *Sci Transl Med*. 2020;12(550).
119. Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. *bioRxiv*. 2020:2020.06.05.135921.
120. Smith CC, Entwistle S, Willis C, Vensko S, Beck W, Garness J, et al. Landscape and Selection of Vaccine Epitopes in SARS-CoV-2. *bioRxiv : the preprint server for biology*. 2020:2020.06.04.135004.
121. Yarmarkovich M, Warrington JM, Farrel A, Maris JM. Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity. *Cell Reports Medicine*. 2020;1(3):100036.
122. Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. *Nature Biotechnology*. 2020;38(7):789-91.
123. Rosado J, Pelleau S, Cockram C, Merkling SH, Nekkab N, Demeret C, et al. Serological signatures of SARS-CoV-2 infection: Implications for antibody-based diagnostics. *medRxiv*. 2020:2020.05.07.20093963.
124. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science (New York, NY)*. 2020;370(6521):1227-30.
125. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. *medRxiv*. 2020:2020.07.21.20159178.
126. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. *The Journal of infectious diseases*. 2020:jiaa618.
127. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. *Immunity*. 2020.
128. Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y, Zhang L-Y, et al. Duration of antibody responses after severe acute respiratory syndrome. *Emerging infectious diseases*. 2007;13(10):1562-4.
129. MO H, ZENG G, REN X, LI H, KE C, TAN Y, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. *Respirology*. 2006;11(1):49-53.
130. Liu W, Fontanet A, Zhang P-H, Zhan L, Xin Z-T, Baril L, et al. Two-Year Prospective Study of the Humoral Immune Response of Patients with Severe Acute Respiratory Syndrome. *The Journal of Infectious Diseases*. 2006;193(6):792-5.
131. Liu L, Xie J, Sun J, Han Y, Zhang C, Fan H, et al. Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients. *Scandinavian journal of infectious diseases*. 2011;43(6-7):515-21.
132. Guo X, Guo Z, Duan C, chen Z, Wang G, Lu Y, et al. Long-Term Persistence of IgG Antibodies in SARS-CoV Infected Healthcare Workers. *medRxiv*. 2020:2020.02.12.20021386.

133. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. *Journal of General Virology*. 2020.
134. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nature communications*. 2020;11(1):4704.
135. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. *Epidemiol Infect*. 1990;105(2):435-46.
136. Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. *Nature medicine*. 2020;26(11):1691-3.
137. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science (New York, NY)*. 2020;368(6493):860-8.
138. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020.
139. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. *The Lancet Infectious Diseases*.
140. Larson D, Brodniak SL, Voegtly LJ, Cer RZ, Glang LA, Malagon FJ, et al. A Case of Early Re-infection with SARS-CoV-2. *Clinical Infectious Diseases*. 2020.
141. Goldman JD, Wang K, Roltgen K, Nielsen SCA, Roach JC, Naccache SN, et al. Reinfection with SARS-CoV-2 and Failure of Humoral Immunity: a case report. *medRxiv*. 2020:2020.09.22.20192443.
142. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Marquez S, Gutierrez B, Rojas-Silva P, et al. COVID-19 Re-Infection by a Phylogenetically Distinct SARS-CoV-2 Variant, First Confirmed Event in South America. *First Confirmed Event in South America(September 3, 2020)*. 2020.
143. Gupta V, Bhoyar RC, Jain A, Srivastava S, Upadhyay R, Imran M, et al. Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. 2020.
144. Shastri J, Parikh S, Agarwal S, Chatterjee N, Pathak M, Sharma C, et al. Whole Genome Sequencing Confirmed SARS-CoV-2 Reinfections Among Healthcare Workers in India with Increased Severity in the Second Episode.
145. To KK-W, Hung IF-N, Chan K-H, Yuan S, To W-K, Tsang DN-C, et al. Serum antibody profile of a patient with COVID-19 reinfection. *Clinical Infectious Diseases*. 2020.
146. Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. *European journal of immunology*. 2020;50(12):2025-40.